Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

BACKGROUND: Bevacizumab has recently been approved by the US Food and Drug Administration for recurrent glioblastoma (GBM). However, patterns of relapse, prognosis, and outcome of further therapy after bevacizumab failure have not been studied systematically. METHODS: We identified patients at Memor...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Iwamoto, F M., Abrey, L E., Beal, K, Gutin, P H., Rosenblum, M K., Reuter, V E., DeAngelis, L M., Lassman, A B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Academy of Neurology 2009
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2839807/
https://ncbi.nlm.nih.gov/pubmed/19822869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181bc0184
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi